FoundationOne Liquid CDx
See a way forward for all patients with solid tumours – using FoundationOne Liquid CDx, our FDA-approved liquid biopsy comprehensive genomic profiling service. This is a minimally-invasive option, alternative or complementary to FoundationOne®CDx at optimal times beneficial to their treatment journey.1–3
Our highly accurate and extensively validated, next-generation liquid biopsy genomic profiling service provides prognostic, diagnostic and predictive insights that inform research or treatment decisions for individual patients across all solid tumours.1,2
Quick and convenient single blood draw
Suitable for patients with all solid tumours
Covers guideline-recommended, and other clinically relevant genomic alterations and signatures for NSCLC, breast, ovarian and prostate cancer, among other solid tumours.2,3,12–31
Reports MSI‡ and bTMB
Supporting personalised decision-making across the patient journey
Part of our proven portfolio of high-quality, FDA-approved comprehensive genomic profiling services for all solid tumours, supporting current and future personalised clinical and research decisions at optimal times beneficial to your patients' treatment journeys1−5
More information about FoundationOne Liquid CDx is coming soon. For more information about FoundationOne Liquid CDx or our portfolio of comprehensive genomic profiling services, please contact your local Roche Foundation Medicine team.
*Base substitutions, insertions or deletions, copy number alterations and gene rearrangements.
†309 genes with complete coding exonic coverage, 15 genes with select intronic or non-coding regions only.
‡FoundationOne Liquid CDx reports MSI-H status.
§75 genes are baited with enhanced sensitivity for all variant types (selected based on increased actionability with current or future targeted therapies; for more information of these 75 genes, please refer to our full gene list); other genomic regions are baited with high sensitivity.
¥Clinical validation based on evidence gathered using an earlier version of Foundation Medicine’s current liquid biopsy service, FoundationOne Liquid CDx. For concordance results between these two tests, please see our full intended use at www.foundationmedicine.com/F1LCDx.
bTMB, blood Tumour Mutational Burden; CDx, companion diagnostic; cfDNA, circulating cell-free DNA; ctDNA, circulating tumour DNA; FDA, U.S. Food and Drug Administration; MSI, Microsatellite Instability; NSCLC, non-small cell lung cancer.
No filter results